Hangzhou Zhongtai Cryogenic Technology Corp (300435) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Hangzhou Zhongtai Cryogenic Technology Corp stock ¥16.17, price ¥13.35, upside +21.2%, quality 75 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range ¥9.20 – ¥34.86 · fair‑value band ¥10.25 – ¥26.34 · the ¥13.35 price screens below the ¥16.17 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Hangzhou Zhongtai Cryogenic Technology in your weekly email
Every Wednesday you see whether Hangzhou Zhongtai Cryogenic Technology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hangzhou Zhongtai Cryogenic Technology Corporation develops, designs, manufactures, and sells cryogenic equipment in China.
Show moreShow less
The company provides engineering services, such as natural gas engineering, air separation, syngas cryogenic separation, olefins separation, specialty gas, and chemical gas purification; manufacturers and sells plate-fin heat exchanger, spiral wound heat exchanger, cold box, distillation column, cryogenic vessel, and skid integration products; and offers EPC services, including natural gas liquefaction plant, natural gas processing plant, air separation plant, rare gas separation, and purification separation plant.
It also exports its products to the United States, Europe, Africa, and Asia. Hangzhou Zhongtai Cryogenic Technology Corporation was founded in 2006 and is headquartered in Hangzhou, China.
Stock analysis
Hangzhou Zhongtai Cryogenic Technology Corp (300435) currently trades at ¥13.35, while our model-based Fair Value estimate is ¥16.17, implying the stock looks roughly 17% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥32.32 per share, and 21 of the 26 models we run sit above the ¥13.35 price.
Bear case: the Dividend Discount group reads lowest at ¥2.79, and 5 of the 26 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ¥10.25 (bear) to ¥26.34 (bull), the price of ¥13.35 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 75/100 (high quality), in the Industrials sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Hangzhou Zhongtai Cryogenic Technology Corp reported revenue of 2.8B CNY in FY2025 versus 2.4B CNY in FY2021, a compound +3.4%/yr. Reported net income was 450M CNY in FY2025, compounding +16.4%/yr from FY2021.
Key figures
Market cap 5.1B CNY (≈ $773M) Small · P/E ratio 12.2 · P/S ratio 1.95 · EPS (TTM) ¥1.09 · Dividend yield 1.9% · Net margin 16.9% · Return on equity 13.4% · Return on assets (EBIT) 6.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 62 out of 100 (low confidence).
What moves the price
The share trades about 62% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Industrials peers we cover trades at −46% fair-value upside, at 21%, 300435 screens cheaper than that median.
Fair Value models
Bear¥10.25Fair Value ¥16.17Bull¥26.34
Price ¥13.35 · Upside +21.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.7180 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF¥15.90¥24.23¥46.5074
EPV¥11.23¥12.67¥13.8774
Growth DCF¥15.11¥25.80¥44.2874
All 26 models by family
DCF Models
FCF DCF¥15.90¥24.23¥46.5074
Owner Earnings¥14.90¥30.14¥58.5870
5Y Revenue Exit¥11.98¥20.29¥36.3568
5Y EBITDA Exit¥16.90¥30.91¥56.5269
5Y P/E Exit¥17.67¥35.63¥58.7266
10Y Revenue Exit¥12.84¥23.16¥34.5364
10Y EBITDA Exit¥16.35¥31.75¥59.6463
10Y P/E Exit¥16.85¥33.10¥60.9359
Earnings-Based
Graham-Dodd¥7.94¥55.37¥77.7061
Lynch FV¥16.62¥23.75¥30.8759
PEG = 1.0¥16.62¥23.75¥30.8755
EPV¥11.23¥12.67¥13.8774
Dividend Discount
Gordon GGM¥1.61¥2.92¥4.0465
DDM Multi-Stage¥1.61¥2.66¥3.1265
Multiples
P/E Multiple¥18.39¥24.52¥30.6563
P/S Multiple¥10.70¥14.26¥17.8358
P/B Multiple¥15.44¥20.59¥25.7455
EV/EBIT¥20.18¥26.33¥32.4766
EV/EBITDA¥18.95¥24.68¥30.4267
EV/Revenue¥10.74¥14.59¥18.4454
Asset-Based
NCAV (Graham)¥1.95¥2.95¥3.6954
Growth DCF
Growth DCF¥15.11¥25.80¥44.2874
Rev-Margin DCF¥11.98¥21.62¥36.0268
Economic Profit
Residual Income¥7.97¥9.31¥13.0173
ROIC Compounder¥12.70¥17.29¥20.8370
Growth Earnings
Growth-Adj P/E¥22.63¥32.32¥42.0265
The fair value above starts from this blend and is adjusted for a year distorted by one-off effects.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+1.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.8%
Start year 2020 (pandemic). Over 10 years: +19.5% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+19.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+17.6%
Dividend (yield on the price)1.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.17.6% vs 10.2%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 20%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−1.1%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −2.7% a year for the price.
Compare Hangzhou Zhongtai Cryogenic Technology Corp with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Industrial Machinery · 814 stocks
Beats the industry median on 14/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score75 · Top 25%
Fair Value upside+21.2% · Top 25%
Profitability
Return on equity (12 months)13.4% · Top 25%
Return on assets9.7% · Top 25%
Net margin (12 months)16.9% · Top 25%
Operating margin (12 months)15.1% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)6.8% · Above median
Dividend yield (12 months)1.9% · Above median
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Specialty Industrial Machinery median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Hangzhou Zhongtai Cryogenic Technology Corp (300435) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of ¥16.17 versus a price of ¥13.35, about +21% upside (undervalued).
What is the fair value of 300435?
Our model-based fair value for Hangzhou Zhongtai Cryogenic Technology Corp is ¥16.17 (as of Nov 8, 2026), built from audited fundamentals. The current price: ¥13.35.
What is the quality score of 300435?
Hangzhou Zhongtai Cryogenic Technology Corp has a Quality Score of 75/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hangzhou Zhongtai Cryogenic Technology Corp (300435)?
Our model-based price target is the fair value of ¥16.17 (as of Nov 8, 2026) from 26 valuation models. Cautious scenario ¥10.25, optimistic scenario ¥26.34. It is a calculation from audited fundamentals, not an analyst target.
What is the Hangzhou Zhongtai Cryogenic Technology Corp stock forecast for 2026?
Our models put fair value at ¥16.17, about +21% upside versus a price of ¥13.35 (undervalued). Cautious scenario ¥10.25, optimistic scenario ¥26.34. The calculation is refreshed regularly with new filings.
What is the revenue of Hangzhou Zhongtai Cryogenic Technology Corp (300435)?
Hangzhou Zhongtai Cryogenic Technology Corp reported trailing-twelve-month revenue of about 2.6B CNY (latest available figure, as of Nov 8, 2026).
Does Hangzhou Zhongtai Cryogenic Technology Corp pay a dividend?
Hangzhou Zhongtai Cryogenic Technology Corp currently shows a dividend yield of 1.87% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Hangzhou Zhongtai Cryogenic Technology Corp (300435) and when is the ex-dividend date?
Hangzhou Zhongtai Cryogenic Technology Corp pays a dividend of ¥0.25 per share a year, a dividend yield of 1.9%. The last ex-dividend date was May 21, 2026. A dividend has been paid every year since at least 2015. The payout ratio is 22.9% of earnings. Free cash flow covers the dividend 4.62 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Hangzhou Zhongtai Cryogenic Technology Corp (300435)?
For today's price to be fair in a discounted-cash-flow model, Hangzhou Zhongtai Cryogenic Technology Corp would have to grow free cash flow by -1.1 % per year for five years (discount rate 10.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.8 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 300435 use?
Our models discount Hangzhou Zhongtai Cryogenic Technology Corp at 10.9 %: a base by market capitalisation (small), damped by beta 0.66, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Hangzhou Zhongtai Cryogenic Technology Corp that is -1.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.9 %) and the same formula as our fair value.
How much growth has Hangzhou Zhongtai Cryogenic Technology Corp (300435) delivered so far?
Over the past 5 years revenue at Hangzhou Zhongtai Cryogenic Technology Corp grew +6.8 % a year. The price currently implies free-cash-flow growth of -1.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Hangzhou Zhongtai Cryogenic Technology Corp (300435) growing?
The median revenue growth in the sector is +7.8 % a year. That is the yardstick for the growth priced into Hangzhou Zhongtai Cryogenic Technology Corp (-1.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Hangzhou Zhongtai Cryogenic Technology Corp (300435)?
The free-cash-flow yield on the price is 8.65 %: that much free cash flow Hangzhou Zhongtai Cryogenic Technology Corp produces per unit of market value. When it exceeds the discount rate of our models (10.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Hangzhou Zhongtai Cryogenic Technology Corp (300435)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hangzhou Zhongtai Cryogenic Technology Corp it is ¥16.17 per share (as of Nov 8, 2026), against a price of ¥13.35. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Hangzhou Zhongtai Cryogenic Technology Corp stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 300435 trades below its calculated fair value: price ¥13.35, fair value ¥16.17, a gap of about +21% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300435?
No. The price is what the market pays today (¥13.35); the fair value is what the company's own numbers justify (¥16.17). For Hangzhou Zhongtai Cryogenic Technology Corp the two are ¥2.82 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hangzhou Zhongtai Cryogenic Technology Corp worth?
The market values Hangzhou Zhongtai Cryogenic Technology Corp at about 5.1B CNY (market capitalisation, as of Nov 8, 2026). Per share that is ¥13.35; our models calculate a fair value of ¥16.17 per share.
What do the bullish and bearish scenarios say about 300435?
Our models span a range for Hangzhou Zhongtai Cryogenic Technology Corp: cautious scenario ¥10.25, base ¥16.17, optimistic ¥26.34 per share (as of Nov 8, 2026, price ¥13.35). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 300435?
Hangzhou Zhongtai Cryogenic Technology Corp trades at a price-to-earnings ratio of 12.2 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥16.17 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings: 36.1. Other multiples: P/B 1.5, P/S 2.0, EV/EBITDA 7.5.
How solid is the balance sheet of Hangzhou Zhongtai Cryogenic Technology Corp (300435)?
Balance-sheet figures for Hangzhou Zhongtai Cryogenic Technology Corp (as of Nov 8, 2026): return on equity 13.4%, debt of 0.03 per unit of equity. They feed the Quality Score of 75/100, which measures business quality independently of the share price.
How far is 300435 from its 52-week high?
Hangzhou Zhongtai Cryogenic Technology Corp trades at ¥13.35, about 62% below its 52-week high of ¥34.86 and 9% above the low of ¥12.22 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥16.17 is for.
Which stocks are comparable to Hangzhou Zhongtai Cryogenic Technology Corp?
From the same area (Industrials) we also value SIE, GE Vernova Inc, Eaton Corporation, Parker-Hannifin Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hangzhou Zhongtai Cryogenic Technology Corp stock attractive at the current price?
The data as of Nov 8, 2026: price ¥13.35, calculated fair value ¥16.17 (+21%), Quality Score 75/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300435 calculated?
We run Hangzhou Zhongtai Cryogenic Technology Corp through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥16.17 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Hangzhou Zhongtai Cryogenic Technology Corp currently trades 17% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hangzhou Zhongtai Cryogenic Technology Corp (300435)?
The closing price on Nov 6, 2026 was ¥13.35. Our model-based fair value is ¥16.17, about +21% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hangzhou Zhongtai Cryogenic Technology Corp right now?
A fairly wide model range (¥10.25 to ¥26.34) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Where does the earnings growth of Hangzhou Zhongtai Cryogenic Technology Corp (300435) come from?
Earnings per share at Hangzhou Zhongtai Cryogenic Technology Corp grew +8.1 % a year from 2013 to 2024. Broken into its drivers: revenue per share +16.4 %, EBIT margin −6.2 %, tax rate −0.8 %, residual (interest, one-offs) −0.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Hangzhou Zhongtai Cryogenic Technology Corp
How large is the market capitalisation of Hangzhou Zhongtai Cryogenic Technology Corp (300435)?
The market capitalisation of Hangzhou Zhongtai Cryogenic Technology Corp is 5.1B CNY (≈ $773M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hangzhou Zhongtai Cryogenic Technology Corp (300435)?
The price-to-sales ratio of Hangzhou Zhongtai Cryogenic Technology Corp is 1.95 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hangzhou Zhongtai Cryogenic Technology Corp (300435)?
Earnings per share at Hangzhou Zhongtai Cryogenic Technology Corp are ¥1.09 (price ÷ EPS = P/E 12.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hangzhou Zhongtai Cryogenic Technology Corp (300435)?
The dividend yield of Hangzhou Zhongtai Cryogenic Technology Corp is 1.9% (payout 22.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hangzhou Zhongtai Cryogenic Technology Corp (300435)?
The net margin of Hangzhou Zhongtai Cryogenic Technology Corp is 16.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hangzhou Zhongtai Cryogenic Technology Corp (300435)?
The return on equity (ROE) of Hangzhou Zhongtai Cryogenic Technology Corp is 13.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hangzhou Zhongtai Cryogenic Technology Corp (300435)?
On an EBIT basis the return on assets of Hangzhou Zhongtai Cryogenic Technology Corp is 6.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hangzhou Zhongtai Cryogenic Technology Corp (300435)?
The operating margin of Hangzhou Zhongtai Cryogenic Technology Corp is 15.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hangzhou Zhongtai Cryogenic Technology Corp (300435)?
Revenue at Hangzhou Zhongtai Cryogenic Technology Corp is growing +6.8% versus a year earlier (3y avg −5.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hangzhou Zhongtai Cryogenic Technology Corp (300435)?
Earnings per share at Hangzhou Zhongtai Cryogenic Technology Corp are growing +157% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Hangzhou Zhongtai Cryogenic Technology Corp (300435) hold?
Hangzhou Zhongtai Cryogenic Technology Corp holds more cash than debt, 676M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Hangzhou Zhongtai Cryogenic Technology Corp in the live analysis
One click puts Hangzhou Zhongtai Cryogenic Technology Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 8, 2026